BLCO Earnings Prediction
The chart below shows how BLCO performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLCO sees a +0.70% change in stock price 10 days leading up to the earnings, and a +0.45% change 10 days following the report. On the earnings day itself, the stock moves by +0.04%. This data can give you a slight idea of what to expect for the next quarter's release.
BLCO Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.20B
18.77%
-1.64%
Gross Margin
55.18%
-2.18%
1.83%
Operating Margin
5.43%
-24.06%
78.62%
Net Margin
0.67%
108.44%
-105.51%
EPS
0.01
104.17%
-102.33%
No Data Available
BLCO Earnings Analysis
Bausch + Lomb Corporation Corporation (BLCO.N) Earnings Conference Call
Positive
Revenue Surge: 1. Strong Revenue Growth: Bausch + Lomb reported total company revenue of $1.196 billion for Q3 2024, reflecting a 19% increase year-over-year and a 10% organic growth.
Pharmaceutical Segment Success: 2. Impressive Pharmaceutical Segment Performance: The Pharmaceutical segment achieved a remarkable 76% constant currency revenue growth, with Miebo and Xiidra contributing significantly to this success.
Surgical Segment Revenue Increase: 3. Surgical Segment Growth: The Surgical segment experienced a 12% constant currency revenue growth, driven by strong performance across all product categories, particularly a 23% increase in premium IOLs.
Vision Care Revenue Increase: 4. Vision Care Segment Expansion: Vision Care revenue reached $684 million, marking a 6% increase, with Daily SiHy lenses growing an impressive 79% in the quarter.
Revenue Guidance Increase: 5. Increased Full Year Revenue Guidance: The company raised its full year revenue guidance to a range of $4.725 billion to $4.825 billion, up from the previous range of $4.7 billion to $4.8 billion, reflecting strong performance and lower expected currency headwinds.
Negative
Eye Vitamins Revenue Decline: 1. Declining Eye Vitamins Sales: The eye vitamins franchise experienced a 9% decline in revenue during Q3 due to disruptions in the drug store channel and retailer inventory rebalancing.
Rising Interest Costs: 2. Increased Interest Expense: Net interest expense for the quarter was $96 million, contributing to financial strain amid ongoing investments in product launches and R&D.
Generic Competition Effects: 3. Generic Competition Impact: Revenue from PROLENSA declined compared to Q3 of 2023 due to a generic entry in Q1 of this year, negatively affecting overall pharmaceutical sales.
Currency Impact on Revenue: 4. Currency Headwinds: Currency fluctuations presented a $5 million headwind to revenue in Q3, impacting overall financial performance despite growth in other areas.
Legislative Impact on Sales: 5. Potential Headwinds from Legislation: The Inflation Reduction Act is anticipated to create headwinds for Xiidra sales in 2025, complicating future revenue projections for the pharmaceutical segment.
BLCO FAQs
How does BLCO typically perform around its earnings report dates?
Is Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BLCO Earning Call Sentiment
Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BLCO.N
-0.88%Positive
The earnings call summary indicates strong financial performance with a 19% YoY revenue growth and raised revenue and EBITDA guidance. Product launches and innovation investments are driving growth, particularly in the pharmaceutical segment. Despite some regulatory and competitive risks, the company's strategic focus and operational excellence are evident. However, the lack of a shareholder return plan and some management hesitance in the Q&A slightly temper enthusiasm. Overall, the positive financial and strategic outlook suggests a stock price increase in the near term.
